Contact Us

Clinical Trials > Pancreas

Please click on a Trial Title for more information

ACELARATE A Phase III, open label, multicentre randomized clinical trial comparing Acelarin (NUC-1031) with Gemcitabine in patient with metastatic pancreatic carcinoma

ESPAC-3 / ESPAC-3(v2) European Study Group for Pancreatic Cancer (ESPAC) - Trial 3. Adjuvant Chemotherapies in Resectable Pancreatic Cancer

Pancreatic cancer is one of the major causes of cancer death in Central and Northern European countries as well as in North America, Australasia and Japan 1. Initial treatment involves surgical resection Despite recent improvements in resection rates for localised pancreatic cancer, long-term survival following surgery alone remains poor with a median of 11-15 months, 2-year survival of 20-40% and 5-year survival of around 10% 2, 3. ESPAC-3 was formulated as a result of the ESPAC-1 study.
ESPAC-4 EUROPEAN STUDY GROUP FOR PANCREATIC CANCER (ESPAC) - Trial 4. Combination versus single agent chemotherapy in resectable pancreatic ductal and peri-ampullary cancers.

Long term survival following resection for pancreatic cancer still needs to be improved. Adjuvant 5-FU/FA demonstrates significant improvement in overall survival following surgery, adjuvant gemcitabine demonstrates a survival advantage following surgical resection for pancreatic cancer. Gemcitabine plus capecitabine improves survival in patients with advanced pancreatic cancer compared with single agent gemcitabine
ESPAC-5F EUROPEAN STUDY GROUP FOR PANCREATIC CANCER - TRIAL 5F Four arm, prospective, multicentre, randomised feasibility trial of immediate surgery compared with neoadjuvant chemotherapies and neoadjuvant chemoradiotherapy.

PANASTA Cattell Warren versus Blumgart techniques of pancreatico-jejunostomy following pacreato-duodenectomy – a double blinded multi-centred trial (Phase III).

PETPANC The Impact of combined modality positron emission tomography with computerised tomography scanning (PET/CT) in the diagnosis and management of pancreatic cancer.

TeloVac A prospective, phase III, controlled, multicentre, randomised clinical trial comparing combination gemcitabine and capecitabine therapy with concurrent and sequential chemoimmunotherapy using a telomerase vaccine in locally advanced and metastatic pancrea

Telomerase is a ribonucleoprotein enzyme which is involved in the DNA replication of the cell cycle. The enzyme is over-expressed in majority of human cancers including 90% of advanced pancreatic cancer patients and therefore is a natural therapeutic target in the treatment of cancer.
The over-expression of Telomerase enables the cancer cells to overcome mortality and therefore be a major contributing factor to progression of cancer. Telomerase is one of the body's own proteins and therefore not recognised or attacked by the immune response. The GV1001 vaccine targets the over-expressed telomerase by enabling the immune response to recognise the enzyme and illicit an immune response against it. As telomerase is over expressed in majority of cancers and plays a leading role in the mortality of cancer cells, GV1001 could in future become a common cancer vaccine.
VIP A prospective, phase II, double blinded, multicentre, randomised clinical trial comparing combination gemcitabine and Vandetanib therapy with gemcitabine therapy alone in locally advanced or metastatic pancreatic carcinoma

Pancreatic cancer is a significant health problem for which there is a huge unmet therapeutic need and which carries a uniquely poor prognosis, with incidence rates and mortality rates being almost equivalent. In the small number of patients who have resectable disease, the five year survival rates are only around 10%. The outcome for patients treated with radiotherapy for locally advanced disease and chemotherapy for metastatic disease is dismal: the most active chemotherapy regimens seldom achieve response rates of over 20%.

Gemcitabine therapy alone is the regulatory standard of care. However, there has been significant growth in the knowledge of the molecular characteristics of the disease and improvements in treatment outcome will only be achieved with the integration of novel therapy targeted to these abnormalities. There is a strong clinical evidence-based rationale for building upon and further investigating the impact of dual epidermal growth factor (EGF) receptor and vascular endothelial growth factor (VEGF) receptor blockade in pancreatic cancer.

Vandetanib is a potent inhibitor of the tyrosine kinase activity of kinase insert domain-containing receptor, an endothelial cell receptor for VEGF and also possesses activity against EGF receptors.

The main aim of the study is to assess if the combination of the two treatments increases the survival time compared to just gemcitabine therapy alone.

All recruitment and site information is updated hourly from LCTU systems